Factors Influencing Early and Late Mortality in Adults with Invasive Pneumococcal Disease in Calgary, Canada: A Prospective Surveillance Study

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Ricketson, Leah J ^a,b   Nettel Aguirre, Alberto ^a,b   Vanderkooi, Otto G ^a,b   Laupland, Kevin B ^a,b   Kellner, James D ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; STREPTOCOCCUS VACCINE;

ADULT; AGE; AGED; ARTICLE; BACTERIUM ISOLATION; CANADA; CHARLSON COMORBIDITY INDEX; COMORBIDITY; DISEASE SEVERITY; DISEASE SURVEILLANCE; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; RISK ASSESSMENT; RISK FACTOR; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CANADA; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 84885120313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071924     Document Type: Article

References (25)

1. Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, et al. (2009) Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 27: 1504-1510. doi:10.1016/j.vaccine.2009.01.013. PubMed: 19171174.
2. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348: 1737-1746. doi:10.1056/NEJMoa022823. PubMed: 12724479.
3. Shapiro ED, Berg AT, Austrian; Shapiro ED, Berg AT,et al (1991) The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325: 1453-1460. doi:10.1056/NEJM199111213252101. PubMed: 1944423. doi:10.1056/NEJM199111213252101 PubMed: 1944423.
4. Benin; Benin AL, O'Brien KL, Watt JP, Reid R,et al (2003) Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. J Infect Dis 188: 81-89. doi:10.1086/375782. PubMed: 12825175. doi:10.1086/375782 PubMed: 12825175.
5. Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR, (2010) Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis 51: 15-22. doi:10.1086/653114. PubMed: 20504233.
6. AUSTRIAN R, GOLD JAustrian R, Gold J (1964) Pneumococcal Bacteremia with Especial Reference to Bacteremic Pneumococcal Pneumonia. Ann Intern Med 60: 759-776. doi:10.7326/0003-4819-60-5-759. PubMed: 14156606.
7. Garau J, Baquero F, Pérez-Trallero E, Pérez JL, Martín-Sánchez AM, et al. (2008) Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect 14: 322-329. doi:10.1111/j.1469-0691.2007.01915.x. PubMed: 18190569.
8. Garcia-Vidal C, Fernández-Sabé N, Carratalà J, Díaz V, Verdaguer R, et al. (2008) Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J 32: 733-739. doi:10.1183/09031936.00128107. PubMed: 18508820.
9. Blanco J, Muriel-Bombín A, Sagredo V, Taboada F, Gandía F, et al. (2008) Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care 12: R158. doi:10.1186/cc6914. PubMed: 19091069.
10. Macias WL, Nelson DR, (2004) Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 32: S223-S228. doi:10.1097/01.CCM.0000126120.49367.AC. PubMed: 15118522.
11. Marrie TJ, Tyrrell GJ, Garg S, Vanderkooi OG, (2011) Factors Predicting Mortality in Invasive Pneumococcal Disease in Adults in Alberta. Medicine (Baltimore) 90: 171-179. doi:10.1097/MD.0b013e31821a5a76. PubMed: 21512414.
12. ClinicalLaboratoryand, (2011). StandardsInstitute. Twenty: Performance Standards for Antimicrobial Susceptibility Testing-first Informational Supplement. Zone Diameter and MIC Interpretive Standards for Streptococcus pneumoniae 1ed. Wayne, PA: Clinical and Laboratory Standards Institute. pp. 96-99.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR, (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383. doi:10.1016/0021-9681(87)90171-8. PubMed: 3558716.
14. Vanderkooi OG, Church DL, Macdonald J, Zucol F, Kellner JD, (2011) Community-Based Outbreaks in Vulnerable Populations of Invasive Infections Caused by Streptococcus pneumoniae Serotypes 5 and 8 in Calgary, Canada. PLOS ONE 6: e28547. PubMed: 22216100.
15. Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, et al. (2009) Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLOS Med 6: e1000081. PubMed: 19468297.
16. Weinberger DM, Harboe ZB, Sanders EA, Ndiritu M, Klugman KP, et al. (2010) Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 51: 692-699. doi:10.1086/655828. PubMed: 20715907.
17. Alanee SR, McGee L, Jackson D, Chiou CC, Feldman C, et al. (2007) Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 45: 46-51. doi:10.1086/518538. PubMed: 17554699.
18. Vallès X, Marcos A, Pinart M, Piñer R, Marco F, et al. (2006) Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased? Chest 130: 800-806. doi:10.1378/chest.130.3.800. PubMed: 16963678.
19. Burman LA, Norrby R, Trollfors B, (1985) Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis 7: 133-142. doi:10.1093/clinids/7.2.133. PubMed: 3890093.
20. Sleeman K, Knox K, George R, Miller E, Waight P, et al. (2001) Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis 183: 239-246. doi:10.1086/317924. PubMed: 11120930.
21. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, et al. (2012) Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380: 37-43. doi:10.1016/S0140-6736(13)60393-1. PubMed: 22579043.
22. Ortqvist A, Hedlund J, Burman L-A, Elbel E, [!(surname)!], öfer M, et al. (1998) Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 351: 399-403.
23. Shapiro ED, Berg AT, Austrian; Shapiro ED, Berg AT,et al (1991) The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325: 1453-1460. doi:10.1056/NEJM199111213252101. PubMed: 1944423. doi:10.1056/NEJM199111213252101 PubMed: 1944423.
24. Feldman C, Anderson R, (2011) Bacteraemic pneumococcal pneumonia: current therapeutic options. Drugs 71: 131-153. doi:10.2165/11585310-000000000-00000. PubMed: 21275443.
25. Balakrishnan I, Crook P, Morris R, Gillespie SH, (2000) Early predictors of mortality in pneumococcal bacteraemia. J Infect 40: 256-261. doi:10.1053/jinf.2000.0653. PubMed: 10908020.